Clinical Trial: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07494045) titled 'Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants' on March 20.

Brief Summary: The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are:

1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules

2. To investigate the safety and tolerability of CTAP101 Capsules

Participants will take a daily dosage of CTAP101...